Alphatec (NASDAQ:ATEC) Director Sells 250,000 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Pelizzon sold 250,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the sale, the director owned 10,895,045 shares of the company’s stock, valued at approximately $224,655,827.90. The trade was a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alphatec Trading Up 5.8%

Shares of NASDAQ:ATEC traded up $1.20 during mid-day trading on Tuesday, reaching $21.83. The stock had a trading volume of 2,887,048 shares, compared to its average volume of 2,130,099. The firm has a 50 day simple moving average of $16.59 and a two-hundred day simple moving average of $14.26. Alphatec Holdings, Inc. has a twelve month low of $8.69 and a twelve month high of $22.00. The firm has a market cap of $3.24 billion, a PE ratio of -19.32 and a beta of 1.17. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to the consensus estimate of $182.78 million. During the same period in the previous year, the company posted ($0.28) EPS. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Alphatec

A number of institutional investors have recently added to or reduced their stakes in ATEC. Emerald Advisers LLC raised its position in Alphatec by 3.8% during the 2nd quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company’s stock worth $18,696,000 after purchasing an additional 60,885 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Alphatec by 7.6% in the first quarter. AQR Capital Management LLC now owns 676,897 shares of the medical technology company’s stock valued at $6,864,000 after buying an additional 47,939 shares during the period. Northern Trust Corp increased its stake in shares of Alphatec by 3.4% in the first quarter. Northern Trust Corp now owns 1,049,469 shares of the medical technology company’s stock valued at $10,642,000 after buying an additional 34,726 shares during the period. Truist Financial Corp bought a new position in shares of Alphatec during the second quarter worth about $216,000. Finally, Voya Investment Management LLC lifted its stake in shares of Alphatec by 60.1% in the first quarter. Voya Investment Management LLC now owns 49,561 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 18,605 shares during the period. 66.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ATEC. Canaccord Genuity Group boosted their price target on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Lake Street Capital set a $25.00 price objective on Alphatec and gave the company a “buy” rating in a research note on Friday, October 31st. Morgan Stanley lifted their target price on Alphatec from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up previously from $20.00) on shares of Alphatec in a report on Friday, October 31st. Finally, Stifel Nicolaus began coverage on shares of Alphatec in a research report on Tuesday, October 28th. They set a “buy” rating and a $20.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.